Sectoral Asset Management — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients.
BiotechDigital HealthHealthtechCambridge, US
Lawrence G. Miller(Executive Officer, Director)inDennis Molnar(Executive Officer)inBarry Wohl(Chief Business Officer)inKetan Mehta(Head of Product and Engineering, Connected Wearables)Ron Farquhar(Director)Gerald Chan(Director)
Co-investorsAlpha Wave GlobalHEALTHCARE ROYALTY PARTNERSMorningside Group
Route 92 Medical develops medical devices and procedural solutions for patients undergoing neurovascular intervention.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Chou(Founder, Chief Executive Officer)Dr. Joey English(Chief Medical Officer)
Co-investorsNovo HoldingsThe Vertical GroupUS Venture PartnersNorwest Venture PartnersU.S. Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.